Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -65.39% is 154% below its 5-year average of -25.74%, around the middle of its 5-year range (-121.37%–6.76%).
9.32% below its 12-month average of -59.82%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -38.53%.
EBITDA MARGIN
-65.39%
EBITDA MARGIN AVG TTM
-59.82%
EBITDA MARGIN AVG 3Y
-34.07%
EBITDA MARGIN AVG 5Y
-25.74%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-9.32%
CURRENT VS 3Y AVG
-91.94%
CURRENT VS 5Y AVG
-154.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Healthcare Triangle, Inc.
Market Cap
$8.36M
EBITDA Margin
-65.39%
TTM Avg
-59.82%
3Y Avg
-34.07%
5Y Avg
-25.74%
Market Cap
$8.29M
EBITDA Margin
-334.15%
TTM Avg
-180.95%
3Y Avg
-121.99%
5Y Avg
-121.99%
Market Cap
$8.25M
EBITDA Margin
-194787.38%
TTM Avg
-191929.49%
3Y Avg
-133856.30%
5Y Avg
-96317.48%
Market Cap
$8.10M
EBITDA Margin
-33055.56%
TTM Avg
-18473.68%
3Y Avg
-9547.23%
5Y Avg
-12604.39%
Market Cap
$7.94M
EBITDA Margin
-638.49%
TTM Avg
-11234.29%
3Y Avg
-10030.31%
5Y Avg
-9704.67%
Market Cap
$7.86M
EBITDA Margin
-951.52%
TTM Avg
-1801.56%
3Y Avg
-1801.56%
5Y Avg
-1801.56%
Market Cap
$9.24M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.79M
EBITDA Margin
-144973.96%
TTM Avg
-73136.05%
3Y Avg
-36678.29%
5Y Avg
-29395.87%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Healthcare Triangle, Inc. (HCTI) | $8.36M | -65.39% | -59.82% | -34.07% | -25.74% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.29M | -334.15% | -180.95% | -121.99% | -121.99% |
| HeartSciences Inc. (HSCS)vs › | $8.25M | -194787.38% | -191929.49% | -133856.30% | -96317.48% |
| GT Biopharma, Inc. (GTBP)vs › | $8.10M | -33055.56% | -18473.68% | -9547.23% | -12604.39% |
| Traws Pharma, Inc. (TRAW)vs › | $7.94M | -638.49% | -11234.29% | -10030.31% | -9704.67% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.86M | -951.52% | -1801.56% | -1801.56% | -1801.56% |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.24M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.76M | N/A | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.79M | -144973.96% | -73136.05% | -36678.29% | -29395.87% |
| Jasper Therapeutics, Inc. (JSPR)vs › | $8.99M | N/A | N/A | N/A | N/A |
Gross Margin
18.4%
EBITDA Margin
-65.4%
Operating Margin
-70.5%
Net Margin
-66.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -38.53% |
| 2026-03-31 | -28.54% |
| 2025-12-31 | -121.37% |
| 2025-09-30 | -72.46% |
| 2025-06-30 | -38.19% |
| 2025-03-31 | -37.42% |
| 2024-12-31 | -38.90% |
| 2024-09-30 | -34.15% |
| 2024-06-30 | -28.28% |
| 2024-03-31 | -28.52% |
| 2023-12-31 | -6.78% |
| 2023-09-30 | -10.44% |
| 2023-06-30 | -9.30% |
| 2023-03-31 | -23.73% |
| 2022-12-31 | -51.59% |
| 2022-09-30 | -11.20% |
| 2022-06-30 | -5.08% |
| 2022-03-31 | -11.42% |
| 2021-12-31 | -27.77% |
| 2021-09-30 | -19.30% |
| 2021-06-30 | 6.76% |
| 2020-09-30 | 5.33% |
| 2020-06-30 | 4.53% |
